Avalo Therapeutics(AVTX) - 2024 Q3 - Quarterly Results

Exhibit 99.1 Avalo Reports Third Quarter 2024 Financial Results and Recent Business Updates • Dosed first patient in Phase 2 LOTUS Trial of AVTX-009 for the treatment of hidradenitis suppurativa (HS), with topline data expected in 2026 • Cash position of approximately $82 million as of September 30, 2024 with subsequent receipt of approximately $58 million of warrant exercise proceeds in 4Q 2024, provides expected runway into at least 2027 WAYNE, PA AND ROCKVILLE, MD, November 7, 2024 — Avalo Therapeutics, ...